-
Hepalink Pharmaceutical’s Enoparin Receives Argentina Approval for Thromboembolic Diseases
•
China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) announced that its subsidiary, Shenzhen Techdow Pharmaceutical Co., Ltd, has received marketing approval from Argentina’s Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) for its Enoparin (enoxaparin) product. The approved specifications include 0.2ml: 20mg, 0.4ml: 40mg, 0.6ml: 60mg, and 0.8ml:…
-
Hepalink Pharmaceutical’s H1710 Heparanase Inhibitor Approved for Phase I Study
•
China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase I clinical study of its proprietary drug candidate H1710, a heparanase (HPA) inhibitor, for the treatment of advanced solid tumors. Drug ProfileH1710 is designed…
-
Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement
•
China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399, HKG: 9989) has announced a product distribution agreement with Zhejiang Yongtai Technology Co., Ltd. The agreement, for which no financial details have been disclosed, appoints Hepalink as the entity responsible for the marketing, promotion, and commercialization of Yongtai’s gabapentin in the…
-
Shenzhen Hepalink’s Enoxaparin Sodium Gets Green Light in Singapore
•
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399), a leading pharmaceutical company based in China, has announced that it has received marketing approval from the Health Sciences Authority of Singapore for its enoxaparin sodium injection in four specifications: 0.2ml:20mg, 0.4ml:40mg, 0.6ml:60mg, and 0.8ml:80mg. The approval is valid for a period…
-
Shenzhen Hepalink Logs 5.55% Q1 Revenue Growth and 133% Net Profit Increase
•
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced its financial results for the first quarter of 2024, reporting a 5.55% year-on-year (YOY) increase in revenues to RMB 1.373 billion (USD 190.3 million). The Chinese pharmaceutical company also saw its net profits surge by 133% YOY to RMB 155…
-
Hepalink Secures TFDA Approval for Enoxaparin Sodium Injection, Expanding Thrombosis Treatment Options in Thailand
•
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399), based in China, has announced that it has received marketing approval from the Thailand Food and Drug Administration (TFDA) for its enoxaparin sodium for injection. The approved specifications include 0.2ml (20mg) and 0.4ml (40mg), indicated for the prevention of venous thromboembolic diseases,…
-
Shenzhen Hepalink Reports 2023 Revenue Dip Amid Sector Demand Declines
•
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399), a leading pharmaceutical company based in China, has released its financial report for 2023. The company reported revenues of RMB 5.431 billion (USD 751 million), marking a decline of 24.1% year-on-year (YOY). Profits for the year reached RMB 802 million (USD 110.9…
-
Hepalink’s Enoxaparin Sodium Injection Receives Marketing Approval in New Zealand
•
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399), a prominent pharmaceutical company based in China, has announced that it has received marketing approval from New Zealand’s Medicines and Medical Devices Safety Authority (MEDSAFE) for its enoxaparin sodium injection, which will be marketed under the trade name Exarane. Enoxaparin sodium injection…
-
Shenzhen Hepalink’s Subsidiary Techdow USA Secures Distribution Rights for ANDA-Approved Drug
•
China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its wholly owned subsidiary, Techdow USA Inc., has entered into a distribution and supply agreement with compatriot firm Chia Tai Tianqing. The agreement centers on Chia Tai Tianqing’s ANDA-approved fosaprepitant dimeglutide in the United States, with Techdow being…
-
Shenzhen Hepalink’s OncoVent Secures Licensing Deal with Orient EuroPharma for Oregovomab
•
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its subsidiary, OncoVent, has entered into a licensing agreement with Taiwan-based Orient EuroPharma Co., Ltd for the immunotherapy drug oregovomab. The agreement grants Orient exclusive commercialization rights to oregovomab in Taiwan, with additional preemptive rights for exclusive sales, marketing,…
